Cryo-EM structure of TGFBIp fibrils driven by a corneal dystrophy–linked mutation enables design of peptide inhibitors of aggregation
- Yi Xiao Jiang
- Lukasz Salwinski
- Michael R. Sawaya
- Peng Ge
- Liisa Lutter
- Xinyi Cheng
- Carolyn J. Hu
- Hillary Hernandez
- David R. Boyer
- Conrad Wang
- Filipe A. Melo
- Duilio Cascio
- David S. Eisenberg
2026-09-08
Corneal dystrophy is a heterogeneous group of diseases which manifests clinically by progressive corneal opacity and diminishing visual acuity. A group of corneal dystrophies are linked to autosomal dominant mutations in transforming growth factor β–induced protein (TGFBIp) and characterized by extracellular amyloid-positive deposits of unknown molecular structure. Here, we determined the cryogenic-electron microscopy (cryo-EM) structure of amyloid fibrils formed by the TGFBIp FAS1-4 domain with corneal dystrophy–linked mutation V624M. The L569 to N609 fibril core, which includes the Y571-R588 segment enriched in patient corneal deposits, forms symmetrical protofilaments with internal solvent channels. Leveraging this structure, we designed peptide inhibitors intended to bind onto fibril ends to block elongation, targeting the unequal growth of symmetrical protofilaments. Our G1 and H4 inhibitors exhibit concentration-dependent reduction of TGFBIp FAS1-4 aggregation as assessed by Thioflavin T, solubility fractionation, and electron microscopy. Our work illustrates how fibril structures can guide rational inhibitor design and suggests the targeting of protein aggregates as a therapeutic approach for corneal and ocular diseases.